Founded in 1997 as an entrepreneurial startup focused on mammalian-derived recombinant cytokines, SBH Sciences has evolved into a leading early discovery CRO advancing drug discovery and development. Through our collaborations with over 400 biotechnology and diagnostic companies, we’ve gained profound experience, establishing ourselves as leaders in oncology, immunotherapy, inflammation, and neurodegenerative diseases. With a proven track record in conducting thousands of binding assays and developing over 350 cell-based biological assays, we are globally recognized as the world leader for measuring the biological activity of cytokines and growth factors. Our unique expertise has contributed to the advancement of seven New Chemical Entities (NCEs), five into clinical trials, and one FDA-approved drug.